BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.17.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260908T160000
DTEND;TZID=America/Los_Angeles:20260908T170000
DTSTAMP:20260812T085719Z
CREATED:20260805T181903Z
LAST-MODIFIED:20260812T085719Z
UID:10946-1788883200-1788886800@thebiocalendar.com
SUMMARY:Beyond breakdowns: Building a culture of proactive maintenance
DESCRIPTION:Across biopharma operations\, reactive “run‑to‑failure” maintenance is one of the biggest hidden drivers of downtime\, deviations\, and escalating lifecycle cost. As the industry moves toward digital maturity\, organizations are shifting from calendar‑based activities to proactive\, engineering‑driven practices that eliminate root causes\, strengthen compliance\, and create the foundation for future predictive and prescriptive strategies. \nProactive maintenance focuses on precision\, consistency\, and early intervention—addressing the mechanical\, procedural\, and environmental factors that lead to recurring failures. This approach not only reduces unplanned downtime and costly emergency service but also supports audit readiness through clear documentation and alignment with Original Equipment Manufacturer (OEM) best practices. For most sites\, these fundamentals deliver the fastest\, highest‑ROI reliability gains long before advanced analytics or AI‑driven tools come into play. \nJoin our session to explore how proactive maintenance can significantly improve equipment uptime\, operational resilience\, and regulatory confidence while preparing your organization for the next stages of digital reliability. \nIn this session\, you will: \nUnderstand the maintenance maturity pyramid and how to intentionally progress through each level\nLearn how proactive\, hands‑on maintenance practices reduce failures and improve cost efficiency\nExplore how lifecycle management integrates with preventive\, proactive\, and predictive strategies\nGain practical tips for implementing proactive maintenance today—and preparing for a predictive or prescriptive culture in the future
URL:https://thebiocalendar.com/event/beyond-breakdowns-building-a-culture-of-proactive-maintenance/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/08/09-08-26-Cytiva-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260902T110000
DTEND;TZID=America/Los_Angeles:20260902T120000
DTSTAMP:20260812T085657Z
CREATED:20260805T181245Z
LAST-MODIFIED:20260812T085657Z
UID:10936-1788346800-1788350400@thebiocalendar.com
SUMMARY:Enabling the full potential of process chromatography
DESCRIPTION:Successfully scaling a purification process from development to GMP manufacturing requires maintaining process performance while minimizing variability. However\, scale-up often introduces challenges that can impact productivity\, recovery\, and overall process efficiency. To mitigate risk\, manufacturers frequently apply conservative safety factors during scale-up—resulting in lower resin utilization\, increased buffer consumption\, longer process times\, and reduced overall productivity. \nWhat if you could maintain the same critical process parameters (CPPs) and critical quality attributes (CQAs) from bench scale through commercial manufacturing with greater confidence and control? \nJoin Repligen for an in-depth discussion on how advanced process control and real-time analytics can help close the gap between process development and manufacturing performance. \nThis webinar will explore key considerations for implementing real-time monitoring and control strategies in chromatography processes. Industry experts will discuss the capabilities of the KRM® chromatography platform and the integration of FlowVPX® Process Analytical Technology (PAT) for in-line product concentration measurement. \nAttendees will learn how these technologies can be applied to support process characterization\, monitor purification performance\, and generate data that may inform scale-up and manufacturing decisions while maintaining focus on critical quality attributes. \nWhat You’ll Learn: \nWhy purification processes often lose efficiency during scale-up\nHow improved process accuracy and precision can increase yield and productivity\nBest practices for maintaining CPPs and CQAs from development through GMP manufacturing\nHow the KRM® platform supports advanced chromatography process control\nHow integrated FlowVPX® PAT enables real-time concentration monitoring and process optimization\nStrategies to improve resin utilization\, reduce buffer consumption\, and maximize recovery \nWho Should Attend? \nProcess Development Scientists\nDownstream Process Engineers\nManufacturing Scientists\nMSAT Professionals\nBiologics and Cell & Gene Therapy Professionals\nPurification and Chromatography Specialists \nRegister Today \nDiscover how real-time process analytics and intelligent chromatography control can help you achieve higher yields\, greater process consistency\, improved resin utilization\, and increased manufacturing productivity—without compromising product quality.
URL:https://thebiocalendar.com/event/enabling-the-full-potential-of-process-chromatography/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/08/09-02-26-Repligen-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260902T110000
DTEND;TZID=America/Los_Angeles:20260902T120000
DTSTAMP:20260812T085636Z
CREATED:20260805T160301Z
LAST-MODIFIED:20260812T085636Z
UID:10929-1788346800-1788350400@thebiocalendar.com
SUMMARY:A CCS is a purpose-built machine\, not a black box: Understand the workings
DESCRIPTION:A contamination control strategy (CCS) is usually treated as a document with sixteen elements assembled\, signed\, and shelved. This webinar offers a new perspective of a CCS as a machine that is not so complex that it cannot be analyzed component by component.
URL:https://thebiocalendar.com/event/a-ccs-is-a-purpose-built-machine-not-a-black-box-understand-the-workings-2/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/08/09-02-25-CAI-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260902T110000
DTEND;TZID=America/Los_Angeles:20260902T120000
DTSTAMP:20260812T085616Z
CREATED:20260805T154159Z
LAST-MODIFIED:20260812T085616Z
UID:10924-1788346800-1788350400@thebiocalendar.com
SUMMARY:AI-Readiness in a Regulated World: A Practical Playbook for Life Sciences
DESCRIPTION:In this practical session\, Jake Walton\, VP of Quality & Compliance at MasterControl\, will share a candid look at how MasterControl approached AI the right way from the start—building human-in-the-loop architecture as a non-negotiable design principle\, aligning every capability to 21 CFR Part 11\, EU MDR\, GDPR\, HIPAA\, and other applicable standards\, and going all the way through ISO 42001 certification for Artificial Intelligence Management Systems.
URL:https://thebiocalendar.com/event/ai-readiness-in-a-regulated-world-a-practical-playbook-for-life-sciences/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/08/09-02-26-MasterControl-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260827T100000
DTEND;TZID=America/Los_Angeles:20260827T110000
DTSTAMP:20260812T085548Z
CREATED:20260728T181700Z
LAST-MODIFIED:20260812T085548Z
UID:10883-1787824800-1787828400@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update: CPHI Milan 2026 Special Edition
DESCRIPTION:Are you making the most of your time at CPHI Milan? \nWatch this free virtual event to evaluate CDMOs\, CMOs\, API suppliers\, packaging providers\, and other outsourcing partners before you arrive onsite. Gain early insight into supplier capabilities\, compare potential partners\, and build a focused meeting strategy that maximizes your time at CPHI Milan. \nRegister today to identify the right partners\, prioritize high-value conversations\, and arrive in Milan ready to make informed outsourcing decisions.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-cphi-milan-2026-special-edition/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/Biocal-27.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260826T110000
DTEND;TZID=America/Los_Angeles:20260826T120000
DTSTAMP:20260730T185612Z
CREATED:20260730T185612Z
LAST-MODIFIED:20260730T185612Z
UID:10908-1787742000-1787745600@thebiocalendar.com
SUMMARY:How Leading Vivariums Are Solving Today’s Toughest Operational Challenges
DESCRIPTION:Every vivarium faces similar pressures and challenges\, but not every team solves them the same way. \nIn this session\, we’ll highlight how organizations like yours are overcoming common challenges in staffing\, colony support\, workflow execution\, and compliance. \nThrough real-world examples\, you’ll gain insight into the decisions\, tradeoffs\, and strategies that helped these teams operate more efficiently and support their scientists more effectively. Leave with useful ideas\, fresh perspectives\, and practical next steps to consider for your own operations. \nYou’ll learn: \n\nHow organizations are maintaining operational continuity when staffing is stretched\nWays to improve animal care consistency and scientific outcomes\nProven approaches to streamline daily workflows and operational execution\nHow teams are scaling operations while maintaining quality and control\nWhat operational models and decisions are driving greater efficiency and reliability\n\nDesigned for: Vivarium directors\, facility managers\, operations leaders\, colony managers\, comparative medicine teams\, animal resources leaders\, in vivo research teams\, and HR professionals hiring to support these functions.
URL:https://thebiocalendar.com/event/how-leading-vivariums-are-solving-todays-toughest-operational-challenges/
LOCATION:Online webinar
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260826T110000
DTEND;TZID=America/Los_Angeles:20260826T120000
DTSTAMP:20260725T054932Z
CREATED:20260720T125405Z
LAST-MODIFIED:20260725T054932Z
UID:10801-1787742000-1787745600@thebiocalendar.com
SUMMARY:Controlling UF/DF with Confidence: How to Define\, Monitor\, and Hit Critical Endpoints
DESCRIPTION:A practical framework for reducing variability\, minimizing manual sampling\, and improving run-to-run consistency with modern UF/DF control strategies. \nAugust 26\, 2026 | 11:00 AM ET \nUltrafiltration Diafiltration (UF/DF) is often treated as a straightforward concentration and buffer-exchange step\, but teams know the reality looks different. Small differences in setup\, endpoint definition\, and in-process decision-making can create major run-to-run variability\, especially as programs move from process development into scale-up and manufacturing. \nIn this webinar\, we will focus on the practical question that determines whether UF/DF is repeatable and scalable: How do you define the right endpoints\, monitor them in real time\, and consistently hit them without relying on constant manual sampling and operator intervention? We will walk through a clear approach to selecting critical UF/DF endpoints (for concentration and diafiltration)\, connecting them to the right measurements\, and using in-line analytics to improve accuracy and consistency. \nKey topics include:\nWhat “critical endpoints” really mean in UF/DF\, and why unclear endpoints drive variability across runs and teams\nEndpoint selection made practical: choosing concentration and diafiltration endpoints that align with process goals and downstream requirements\nHow real-time\, in-line concentration data enables automated control\, reducing manual sampling and dilution while improving efficiency\, consistency\, and decision-making\nReducing variability across scales by linking endpoint definition\, monitoring strategy\, and execution consistency from PD through manufacturing\nTroubleshooting through the lens of control: how clearer endpoints and better monitoring help teams respond faster to instability and performance drift \nWhether you are building a UF/DF strategy in development\, preparing for tech transfer\, or tightening control in manufacturing\, this session will provide practical guidance for making UF/DF easier to run\, easier to scale\, and easier to reproduce.
URL:https://thebiocalendar.com/event/controlling-uf-df-with-confidence-how-to-define-monitor-and-hit-critical-endpoints/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-26-26-Repligen-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260825T110000
DTEND;TZID=America/Los_Angeles:20260825T120000
DTSTAMP:20260812T085518Z
CREATED:20260731T151018Z
LAST-MODIFIED:20260812T085518Z
UID:10912-1787655600-1787659200@thebiocalendar.com
SUMMARY:Optimizing Movement Disorder Clinical Trials: A Focus on Parkinson's Disease
DESCRIPTION:Join experts from Dr. Vince Clinical Research\, along with moderator Polly Dawkins of the Davis Phinney Foundation\, for a practical discussion on designing and executing successful Parkinson’s disease clinical trials. The session will explore symptomatic and disease-modifying study designs\, endpoint selection\, emerging research trends and operational challenges. Attendees will gain real-world insights to help advance Parkinson’s disease programs from early development through NDA submission.
URL:https://thebiocalendar.com/event/optimizing-movement-disorder-clinical-trials-a-focus-on-parkinsons-disease/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-25-26-DVCR-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260825T110000
DTEND;TZID=America/Los_Angeles:20260825T120000
DTSTAMP:20260812T085500Z
CREATED:20260730T121133Z
LAST-MODIFIED:20260812T085500Z
UID:10897-1787655600-1787659200@thebiocalendar.com
SUMMARY:Characterizing Process Performance and Robustness in an End-to-End Cryopreserved Autologous CAR-T/TCR Workflow
DESCRIPTION:Explore data from an end-to-end CAR-T workflow using cryopreserved leukopaks. This session will examine how key process parameters affect cell recovery\, viability\, consistency\, and scalability across washing\, cryopreservation\, thawing\, and final formulation. \nAttendees will learn practical strategies for defining operating ranges\, reducing variability\, and building more robust closed-system autologous manufacturing workflows.
URL:https://thebiocalendar.com/event/characterizing-process-performance-and-robustness-in-an-end-to-end-cryopreserved-autologous-car-t-tcr-workflow/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-25-26-CARR-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260825T110000
DTEND;TZID=America/Los_Angeles:20260825T120000
DTSTAMP:20260812T085441Z
CREATED:20260727T143248Z
LAST-MODIFIED:20260812T085441Z
UID:10870-1787655600-1787659200@thebiocalendar.com
SUMMARY:Driving Measurable Productivity Gains in CHO Cell Culture
DESCRIPTION:Achieving consistent upstream performance remains a critical challenge as bioprocesses become more complex and quality expectations continue to rise. From variability in raw materials to maintaining cell growth\, productivity\, and product quality across platforms\, process developers are under increasing pressure to build more robust and reliable manufacturing processes. \nJoin this webinar to explore practical strategies for optimizing upstream CHO cell culture performance through media component selection and process design. Through real-world application data and case studies spanning both monoclonal antibodies and emerging antibody modalities\, our experts will share insights into reducing variability\, improving process consistency\, and enhancing key cell culture outcomes. \nLearning Objectives:\n~ Understand the impact raw material variability can have on upstream process performance and product quality\n~ Explore approaches to improving consistency\, cell growth\, viability\, and productivity in CHO-based processes\n~ Review case studies demonstrating successful media optimization strategies across multiple antibody production workflows\n~ Gain practical insights to support media selection and upstream process development decisions
URL:https://thebiocalendar.com/event/driving-measurable-productivity-gains-in-cho-cell-culture/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-25-26-Thermo-Reg-1920x250-rev.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260821T110000
DTEND;TZID=America/Los_Angeles:20260821T120000
DTSTAMP:20260812T085415Z
CREATED:20260728T181155Z
LAST-MODIFIED:20260812T085415Z
UID:10878-1787310000-1787313600@thebiocalendar.com
SUMMARY:Container Closure Integrity Testing: Selecting a Test Method for your Container System
DESCRIPTION:Join us for a practical discussion on selecting the right Container Closure Integrity Testing (CCIT) method for your container system. Learn how deterministic and probabilistic approaches compare\, understand the impact of package design and product characteristics on method selection\, and gain a risk-based framework for justifying your CCIT strategy to regulators.
URL:https://thebiocalendar.com/event/container-closure-integrity-testing-selecting-a-test-method-for-your-container-system/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-21-26-Pace-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260820T110000
DTEND;TZID=America/Los_Angeles:20260820T120000
DTSTAMP:20260812T144002Z
CREATED:20260729T150317Z
LAST-MODIFIED:20260812T144002Z
UID:10888-1787223600-1787227200@thebiocalendar.com
SUMMARY:Where Precision Drives Progress: Meeting the Rising Complexity of Modern Clinical Trials
DESCRIPTION:Explore how leading teams are using trusted data and targeted AI to design\, plan\, and execute trials with the confidence today’s science requires. \nLearning outcomes:\n– Understand what’s driving trial complexity\n– Design protocols with confidence using real data + AI\n– Select sites based on holistic drivers of outcomes; access\, experience and past performance\n– Rethink patient recruitment as the critical success factor\n– Align with evolving regulatory expectations (ICH GCP E6 R3)
URL:https://thebiocalendar.com/event/where-precision-drives-progress-meeting-the-rising-complexity-of-modern-clinical-trials/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-20-26-Citeline-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260820T110000
DTEND;TZID=America/Los_Angeles:20260820T120000
DTSTAMP:20260725T055023Z
CREATED:20260724T110739Z
LAST-MODIFIED:20260725T055023Z
UID:10851-1787223600-1787227200@thebiocalendar.com
SUMMARY:CAR-T for Relapsed/Refractory AML: From Discovery to First-in-Human Active Phase 1 Evaluation
DESCRIPTION:Join Dr. Marco Davila to explore a novel anti-CD83 CAR-T design for relapsed/refractory AML that overcomes myelosuppression barriers. Register for the live session. \nDeveloping effective Chimeric Antigen Receptor (CAR) T-cell therapies for Acute Myeloid Leukemia (AML) remains one of the most formidable frontiers in cellular immunotherapy. Unlike lymphoid malignancies where lineage-specific targets like CD19 or BCMA offer a clear therapeutic window\, AML presents a severe biological bottleneck. The vast majority of well-characterized myeloid antigens (such as CD33 or CD123) are shared with healthy hematopoietic stem and progenitor cells (HSPCs). Consequently\, conventional CAR-T approaches frequently induce prolonged\, life-threatening myelosuppression and bone marrow aplasia severely limiting their clinical utility. This webinar by Dr. Marco Davila will explore a paradigm-shifting strategy developed at Roswell Park Comprehensive Cancer Center that addresses this exact barrier: a novel CAR-T design targeting the CD83 antigen. \nOur discussion will center on the unique biology of CD83\, a protein highly expressed on malignant AML blasts but distinctively regulated in healthy tissues\, offering a pathway to selectively suppress leukemia cells while sparing critical progenitor stem cells. Moving from bench to bedside\, we will detail the rigorous process development and GMP manufacturing frameworks involved in generating this CAR-T cell therapy to be tested in clinic. Finally\, we will share insights into the initiation and objectives of the first-of-its-kind\, active Phase 1 clinical trial evaluating autologous anti-CD83 CAR-T cell infusions in patients with relapsed or refractory AML. Join us to discover how this dual-action architecture reshapes safety\, efficacy\, and translation benchmarks in the myeloid cell therapy space.
URL:https://thebiocalendar.com/event/car-t-for-relapsed-refractory-aml-from-discovery-to-first-in-human-active-phase-1-evaluation/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-20-26-Miltenyi-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260820T110000
DTEND;TZID=America/Los_Angeles:20260820T120000
DTSTAMP:20260725T055053Z
CREATED:20260717T115757Z
LAST-MODIFIED:20260725T055053Z
UID:10796-1787223600-1787227200@thebiocalendar.com
SUMMARY:FDA Engagement Strategies And Best Practices Amid Agency Changes
DESCRIPTION:How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies? \nShould companies adjust their agency communication strategies or ask new questions during meetings? Our deeply experienced panelists will discuss key changes at the FDA\, how companies can get the most out of agency interactions\, and strategies to lower risks and avoid regulatory surprises. \nRegister for free today and secure your spot for this important virtual event.
URL:https://thebiocalendar.com/event/fda-engagement-strategies-and-best-practices-amid-agency-changes/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/26_08-LSL-HTML-600x300-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260819T110000
DTEND;TZID=America/Los_Angeles:20260819T120000
DTSTAMP:20260812T085350Z
CREATED:20260803T190658Z
LAST-MODIFIED:20260812T085350Z
UID:10919-1787137200-1787140800@thebiocalendar.com
SUMMARY:Take the Turbulence Out of Your Transfections: Reduce AAV Titer Variability by Optimizing Delivery
DESCRIPTION:In this webinar we expand on some of the processes most vulnerable to introducing titer variability\, as well as strategies to overcome sources of variability when they are unavoidable to maintain high-titer production.
URL:https://thebiocalendar.com/event/take-the-turbulence-out-of-your-transfections-reduce-aav-titer-variability-by-optimizing-delivery/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/08/08-19-26-Mirus-Bio-Reg-1920x250-rev.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260818T130000
DTEND;TZID=America/Los_Angeles:20260818T140000
DTSTAMP:20260725T055605Z
CREATED:20260721T180509Z
LAST-MODIFIED:20260725T055605Z
UID:10816-1787058000-1787061600@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update August 2026: Oral Solid Dose Formulation
DESCRIPTION:Oral solid dose programs can run into costly scale-up challenges when early formulation and process decisions aren’t built for long-term manufacturability. \nJoin leading CDMO experts on August 18 at 1:00 PM ET to explore how excipient selection\, granulation strategy\, particle engineering\, and process design can impact tech transfer\, validation\, and commercial manufacturing. \nRegister now to gain practical insights for evaluating CDMO capabilities\, identifying scale-up risks earlier\, and making more informed partner selection decisions.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-august-2026-oral-solid-dose-formulation/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/Biocal-26.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260818T110000
DTEND;TZID=America/Los_Angeles:20260818T120000
DTSTAMP:20260725T055842Z
CREATED:20260721T180321Z
LAST-MODIFIED:20260725T055842Z
UID:10811-1787050800-1787054400@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update August 2026: Nanoparticles
DESCRIPTION:Nanoparticle programs can stall when early formulation choices fail to hold up through scale-up\, tech transfer\, and manufacturing. \nJoin leading CDMO experts on August 18 at 11:00 AM ET to learn how decisions around lipid or polymer selection\, particle engineering\, process design\, and manufacturability can impact downstream success. \nRegister now to gain practical insights that will help you evaluate CDMO approaches\, ask sharper formulation questions\, and reduce risk before nanoparticle challenges become costly development setbacks.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-august-2026-nanoparticles/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/Biocal-25.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260818T110000
DTEND;TZID=America/Los_Angeles:20260818T120000
DTSTAMP:20260714T195850Z
CREATED:20260714T125327Z
LAST-MODIFIED:20260714T195850Z
UID:10775-1787050800-1787054400@thebiocalendar.com
SUMMARY:The Future of Cell Culture Media Development: Predictive Modeling and AI
DESCRIPTION:As biologics developers work to improve productivity\, reduce development timelines\, and manage manufacturing costs\, traditional media optimization approaches can become increasingly resource intensive. Predictive modeling is emerging as a complementary approach that can help integrate biological knowledge\, process data\, and artificial intelligence (AI) to support more efficient media development. \nIn this webinar\, Thermo Fisher Scientific specialists discuss how predictive modeling and AI are being applied to cell culture media development. Learn how computational modeling can help identify promising formulation strategies\, focus experimental efforts\, and support more informed development decisions while maintaining the critical role of scientific expertise. \nIn this session\, you will learn about:\n~ The emerging role of predictive modeling in cell culture media development\n~ How AI can help support formulation optimization\n~ The value of integrating biological\, analytical\, and process data\n~ How predictive modeling and scientific expertise can work together to inform development decisions \nKey topics include:\n~ Challenges with traditional media optimization approaches\n~ AI-guided formulation design and in silico modeling\n~ Human expertise in predictive model development and validation\n~ Cross-functional collaboration in AI-enabled media development\n~ Predictive modeling in biologics development \nDiscover how predictive modeling and AI are helping shape the future of cell culture media development by supporting more informed\, data-driven approaches to media optimization.
URL:https://thebiocalendar.com/event/the-future-of-cell-culture-media-development-predictive-modeling-and-ai/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-18-26-Thermo-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260813T130000
DTEND;TZID=America/Los_Angeles:20260813T140000
DTSTAMP:20260714T195655Z
CREATED:20260714T125112Z
LAST-MODIFIED:20260714T195655Z
UID:10770-1786626000-1786629600@thebiocalendar.com
SUMMARY:From Data to Decisions: AI and Multi-Omics for Cell Culture Development
DESCRIPTION:As biologics developers work to improve productivity\, maintain product quality\, and accelerate development timelines\, traditional optimization approaches can sometimes reach a point of diminishing returns. While cell culture processes generate vast amounts of biological and process data\, extracting actionable insights from that information remains a significant challenge. \nIn this webinar\, Thermo Fisher Scientific specialists discuss how the integration of multi-omics data\, artificial intelligence (AI)\, and deep cell culture expertise can help uncover the biological mechanisms driving process performance. Learn how AI-enabled analytics can support more informed decision-making\, identify optimization opportunities\, and accelerate media and process development. \nIn this session\, you will learn about:\n~ The role of multi-omics in understanding cell culture performance\n~ How AI is helping uncover biological drivers of productivity and quality\n~ Emerging applications of predictive modeling in media and process development\n~ New approaches to turning complex biological data into actionable insights \nKey topics include:\n~ Case study: using AI and metabolomics to overcome optimization plateaus\n~ Multi-omics approaches in cell culture development\n~ AI-enabled data integration and pattern recognition\n~ Understanding productivity and product quality trade-offs\n~ From biological data to development decisions \nDiscover how AI and multi-omics are helping developers move beyond descriptive analytics toward more predictive\, mechanism-based approaches to cell culture optimization.
URL:https://thebiocalendar.com/event/from-data-to-decisions-ai-and-multi-omics-for-cell-culture-development/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-13-26-Thermo-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260813T110000
DTEND;TZID=America/Los_Angeles:20260813T120000
DTSTAMP:20260725T055907Z
CREATED:20260721T175625Z
LAST-MODIFIED:20260725T055907Z
UID:10806-1786618800-1786622400@thebiocalendar.com
SUMMARY:When Unexpected Particles Threaten Your Biologic
DESCRIPTION:Unexpected particle findings can raise critical questions about product quality\, patient safety\, and regulatory compliance. \nJoin KBI Biopharma’s experts to learn how clinical in-use studies and advanced particle forensics can help identify particle sources\, assess risk\, and build regulator-ready evidence for confident decision-making. \nRegister now to discover practical strategies for accelerating investigations\, supporting development timelines\, and responding effectively when unexpected particles threaten your biologic.
URL:https://thebiocalendar.com/event/when-unexpected-particles-threaten-your-biologic/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-13-26-KBI-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260813T100000
DTEND;TZID=America/Los_Angeles:20260813T120000
DTSTAMP:20260630T200519Z
CREATED:20260629T132259Z
LAST-MODIFIED:20260630T200519Z
UID:10668-1786615200-1786622400@thebiocalendar.com
SUMMARY:Commercial Readiness Solutions
DESCRIPTION:The journey from a successful lab result to a reliable\, GMP-compliant product is rarely a straight line. It’s a transition filled with technical hurdles\, regulatory pressure\, and the constant challenge of scaling without compromise. \nWe created the Commercial Readiness Solutions session to help you navigate this transition. This virtual event is designed to be highly practical – moving past high-level theory to focus on the specific tools and partnerships needed to solve the real-world bottlenecks in your production lifecycle. \nJoin us to evaluate the solutions and technologies essential for a sustainable commercial platform\, including: \nGMP Execution & Inspection Readiness: Building the protocols and confidence to meet global regulatory standards.\nManufacturing Scale-up: Leveraging closed-system automation to reduce manual risk and variability.\nContamination Control: Implementing advanced strategies to ensure sterility and product safety at scale.\nQC & Release Testing: Optimizing testing strategies to accelerate the path from the facility to the patient.\nValidation & Data Integrity: Ensuring your process documentation is robust\, transparent\, and compliant.\nDigital Infrastructure: Integrating eQMS\, MES\, and LIMS for a seamless\, paperless manufacturing environment. \nPractical Insights\, Not Just Presentations. Through solution-focused sessions and real-world case studies\, this event will highlight the supplier capabilities and technologies that reduce risk and accelerate your timelines. Our goal is to show you how to strengthen your operational resilience – maintaining the highest quality standards without sacrificing the throughput you need to stay competitive. \nMove Forward with Confidence. Whether you are preparing for your next inspection\, refining your control strategy\, or building a repeatable platform for the global market\, we are here to connect you with the right expertise. Join us to find the tools and insights you need to move confidently from development to commercial success – bringing life-changing therapies to more patients\, faster.
URL:https://thebiocalendar.com/event/commercial-readiness-solutions/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/08-2026-CGTE-1280x720-COMMERCIAL-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260812T130000
DTEND;TZID=America/Los_Angeles:20260812T140000
DTSTAMP:20260714T195536Z
CREATED:20260708T123716Z
LAST-MODIFIED:20260714T195536Z
UID:10734-1786539600-1786543200@thebiocalendar.com
SUMMARY:IRB in Action: A Live Mock Board Review
DESCRIPTION:Join Univo IRB for a unique educational webinar that takes attendees inside the IRB decision-making process through a live mock board review. Using a fictional agenda item based on real clinical and ethical challenges\, experienced IRB members will evaluate key protocol considerations including risk-benefit assessment\, informed consent\, participant protections\, recruitment strategies\, and regulatory compliance. This session is designed to help sponsors\, CROs\, sites\, and clinical research professionals better understand how IRBs review protocols and make decisions that support ethical\, compliant research.
URL:https://thebiocalendar.com/event/irb-in-action-a-live-mock-board-review/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/Untitled-design-66.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260812T100000
DTEND;TZID=America/Los_Angeles:20260812T120000
DTSTAMP:20260630T200536Z
CREATED:20260629T132028Z
LAST-MODIFIED:20260630T200536Z
UID:10663-1786528800-1786536000@thebiocalendar.com
SUMMARY:Gene Therapy Solutions
DESCRIPTION:Cell & Gene Tech Expo offers a live virtual experience designed to empower industry professionals in sourcing best-fit solutions for their cell and gene therapy manufacturing needs. Through this series of digital sessions\, attendees will have the chance to explore the newest equipment and solutions offered by our presenters\, aimed at addressing the current challenges within the cell and gene therapy manufacturing process. This interactive online experience ensures convenience and accessibility\, fostering an environment of learning and innovation for all participants. \nThe attendees of the Gene Therapy Equipment session will have the chance to explore the newest equipment and solutions offered by our presenting suppliers. \nWhat can you expect? Short\, digital presentations with live interaction. You will have the opportunity to ask questions to better understand if suppliers can meet your needs – all from the convenience of your computer!
URL:https://thebiocalendar.com/event/gene-therapy-solutions/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/08-2026-CGTE-1280x720-GENE-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260811T100000
DTEND;TZID=America/Los_Angeles:20260811T120000
DTSTAMP:20260630T200555Z
CREATED:20260629T131816Z
LAST-MODIFIED:20260630T200555Z
UID:10658-1786442400-1786449600@thebiocalendar.com
SUMMARY:Cell Therapy Solutions
DESCRIPTION:Cell & Gene Tech Expo offers a live virtual experience designed to empower industry professionals in sourcing best-fit solutions for their cell and gene therapy manufacturing needs. Through this series of digital sessions\, attendees will have the chance to explore the newest equipment and solutions offered by our presenters\, aimed at addressing the current challenges within the cell and gene therapy manufacturing process. This interactive online experience ensures convenience and accessibility\, fostering an environment of learning and innovation for all participants. \nThe attendees of the Gene Therapy Equipment session will have the chance to explore the newest equipment and solutions offered by our presenting suppliers. \nWhat can you expect? Short\, digital presentations with live interaction. You will have the opportunity to ask questions to better understand if suppliers can meet your needs – all from the convenience of your computer!
URL:https://thebiocalendar.com/event/cell-therapy-solutions/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/08-2026-CGTE-1280x720-CELL-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260806T110000
DTEND;TZID=America/Los_Angeles:20260806T120000
DTSTAMP:20260714T195510Z
CREATED:20260708T142705Z
LAST-MODIFIED:20260714T195510Z
UID:10739-1786014000-1786017600@thebiocalendar.com
SUMMARY:Built for Growth: Engineering Flexible and Scalable Bioprocessing Strategies
DESCRIPTION:As biopharmaceutical manufacturing becomes increasingly global\, organizations face growing challenges in balancing flexibility\, standardization\, and scalability. CDMOs must accommodate sponsor-specific requirements\, manufacturers must transfer processes across geographically dispersed facilities\, and growing programs require equipment platforms that can scale without introducing unnecessary risk or complexity. \nSuccessfully navigating these challenges requires more than equipment; it requires a partner who can help define standards\, align stakeholders\, and anticipate future needs before they become obstacles. \nIn this webinar\, we will explore how a collaborative\, engineering-first approach can help biopharmaceutical manufacturers build more resilient and adaptable manufacturing strategies. Through real-world examples\, attendees will learn how organizations have addressed sponsor-driven variability in single-use filtration\, established global design standards across multiple manufacturing sites\, and developed scalable platform strategies that support seamless progression from clinical to commercial manufacturing. \nJoin us to discover how thoughtful system design\, strategic planning\, and trusted partnerships can help future-proof manufacturing operations while reducing risk\, simplifying technology transfer\, and supporting long-term growth. \nKey Objectives:\n~ Identify key strategies for balancing flexibility\, standardization\, and scalability in modern biopharmaceutical manufacturing\n~ Understand how collaborative engineering and trusted partnerships can simplify technology transfer\, align stakeholders\, and reduce operational risk\n~ Explore real-world approaches to designing manufacturing platforms that support sponsor variability today while enabling seamless growth from clinical to commercial production
URL:https://thebiocalendar.com/event/built-for-growth-engineering-flexible-and-scalable-bioprocessing-strategies/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/08-06-26-Asahi-Kasei-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260805T110000
DTEND;TZID=America/Los_Angeles:20260805T120000
DTSTAMP:20260714T195443Z
CREATED:20260714T152304Z
LAST-MODIFIED:20260714T195443Z
UID:10785-1785927600-1785931200@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update: Cell Line Development
DESCRIPTION:In this virtual event\, leading CDMOs will share how host selection\, vector design\, and clone screening strategies influence manufacturability from early development through commercialization. \nJoin us to learn what to evaluate early\, how to reduce downstream risk\, and how to make more informed cell line development decisions.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-cell-line-development/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/Biocal-22.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260804T110000
DTEND;TZID=America/Los_Angeles:20260804T120000
DTSTAMP:20260714T195401Z
CREATED:20260714T151822Z
LAST-MODIFIED:20260714T195401Z
UID:10780-1785841200-1785844800@thebiocalendar.com
SUMMARY:Charting a Direct Pathway from Academia To CDMOs
DESCRIPTION:Moving promising research from the university lab to the CDMO suite requires more than breakthrough science—it requires the right documentation\, development strategy\, and manufacturing readiness. \nIn this Outsourced Pharma Live discussion\, industry experts explore how academic innovators and CDMOs can better align earlier\, build stronger technical packages\, and create a smoother path to outsourced development and manufacturing. \nWatch the discussion to learn how to make academic programs more CDMO-ready and accelerate the journey from discovery to execution.
URL:https://thebiocalendar.com/event/charting-a-direct-pathway-from-academia-to-cdmos/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/Biocal-21.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260804T110000
DTEND;TZID=America/Los_Angeles:20260804T120000
DTSTAMP:20260714T195429Z
CREATED:20260708T142914Z
LAST-MODIFIED:20260714T195429Z
UID:10744-1785841200-1785844800@thebiocalendar.com
SUMMARY:Ensuring Successful Technology Transfer In ADC Development
DESCRIPTION:Technology transfers can introduce risk and create knowledge gaps at every stage of development\, whether it’s moving a process from development to manufacturing\, transferring methods between analytical labs\, or onboarding a new CDMO partner. This is especially true in the development of antibody-drug conjugates (ADC)\, where the complexity of conjugation processes\, analytical characterization\, and specialized manufacturing expertise is often distributed across multiple CDMO partners. \nJoin Bioprocess Online’s Tyler Menichiello for an interactive panel discussion with Sourav Kundu\, Ph.D.\, senior vice president of development and manufacturing at NextCure\, and Will Olughu\, Ph.D.\, global CMC lead and senior principal scientist at Ipsen\, as they explore practical ways to navigate the transfer of process and analytical knowledge in ADC development to reduce risk and avoid delays.
URL:https://thebiocalendar.com/event/ensuring-successful-technology-transfer-in-adc-development/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/07/26_08-BPOL-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260730T110000
DTEND;TZID=America/Los_Angeles:20260730T120000
DTSTAMP:20260630T200611Z
CREATED:20260629T174444Z
LAST-MODIFIED:20260630T200611Z
UID:10673-1785409200-1785412800@thebiocalendar.com
SUMMARY:Breaking the Bottleneck: How Modular Workflows Are Redefining CAR T Manufacturing Performance\, Flexibility\, and Scalability
DESCRIPTION:As cell therapies advance toward commercial-scale manufacturing\, developers can face increasing pressure to balance performance\, scalability\, and process flexibility. Flexible modular workflows are emerging as a powerful approach for scalable cell therapy manufacturing\, enabling enhanced process control\, workflow adaptability\, and operational efficiency while maintaining consistency across the manufacturing pipeline. These advantages can be particularly valuable in environments where evolving process requirements may challenge more fixed manufacturing approaches. \nIn this webinar\, we will explore how modular Gibco™ CTS™ workflows compare to an integrated system across critical CAR T manufacturing quality attributes\, including transduction efficiency\, T cell activation\, expansion\, and phenotype preservation. Data demonstrate that modular workflows can achieve high transduction efficiency (up to ~80% by day 8)\, increased CAR+ T cell yields\, and enhanced enrichment of stem cell–like memory (TSCM) populations\, which can be key factors associated with improved therapeutic potential. \nWe will also highlight how flexibility in workflow design enables parallel processing\, reduced instrument lock times\, and improved operational efficiency\, without compromising cell quality metrics such as purity and isolation efficiency. Attendees will gain practical insights into how modular strategies can future-proof manufacturing processes and support both early development and commercial-scale production. \nKey Learning Objectives \nUnderstand how modular workflows impact critical CAR T manufacturing attributes\, including transduction efficiency\, expansion\, and T cell phenotype\nEvaluate the trade-offs between integrated and modular systems in terms of scalability\, flexibility\, and operational efficiency\nLearn how flexible workflow design can enable parallel processing\, reduce bottlenecks\, and support evolving process requirements
URL:https://thebiocalendar.com/event/breaking-the-bottleneck-how-modular-workflows-are-redefining-car-t-manufacturing-performance-flexibility-and-scalability/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/07-30-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260729T130000
DTEND;TZID=America/Los_Angeles:20260729T140000
DTSTAMP:20260630T200627Z
CREATED:20260630T142856Z
LAST-MODIFIED:20260630T200627Z
UID:10693-1785330000-1785333600@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update July 2026: Large Molecule
DESCRIPTION:Explore the latest large molecule manufacturing capabilities from leading CDMOs in this informative webinar. \nLearn about advances in cell line development\, fermentation\, purification\, process optimization\, and scale-up\, while gaining insight into available capacity\, facility locations\, and timelines. \nWhether you’re evaluating manufacturing partners or planning future biologics production\, this session offers a practical overview to help you identify the right CDMO for your program.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-july-2026-large-molecule/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/Outsourced-Pharma-Capabilities-Update-July-2026-3.png
END:VEVENT
END:VCALENDAR